Joint Corp
Joint Corp operates in the healthcare facilities and services industry, focusing on biotechnology, and generates revenue primarily through its services and equipment offerings.
Business. Joint Corp (JYNT.O) is a healthcare company operating within the Healthcare Facilities & Services industry, with activities focused on biotechnology. The firm generates revenue through service-based models typical of the healthcare services sector. Specific details regarding its operating segments, headquarters location, and primary stock exchange listing are not available in the provided data.
Analyst recommendations
4 analysts · consensus HoldAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
6Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ2 2026 earnings (expected)2026-07-28 · estimated
- Macro
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-07-08 · AU
- Rate decisionBank of Canada rate decision (press conf.)2026-07-15 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-07-16 · EU
- Rate decisionBank of Japan rate decision (press conf.)2026-07-16 · JP
- Rate decisionFederal Reserve rate decision (press conf.)2026-07-29 · US
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Joint Corp (JYNT.O) is currently undergoing its first formal analysis, meaning there is no prior historical basis for computing material changes or delta metrics. Consequently, the most significant immediate observation is the establishment of a baseline rather than a specific operational shift. The company’s profile is defined by a lean leadership structure with two officers and a modest analyst following of two, indicating limited institutional scrutiny at this stage. In terms of market visibility, Joint Corp is not currently a member of any major indices, which may limit its exposure to passive investment flows. However, the company maintains a shareholder base comprising 20 top holders, suggesting a degree of concentrated ownership despite the lack of broad index inclusion. This structure implies that price movements may be more sensitive to actions by these key stakeholders than to broader market trends. Recent monitoring data reveals a notable spike in activity on June 14, 2026, when one dispatch was recorded, breaking a streak of zero daily dispatches from May 25 through June 13. This isolated event marks the first instance of tracked communication or data release in the observed 30-day window, potentially signaling the beginning of increased transparency or a specific corporate announcement that warrants further investigation. The broader context for Joint Corp includes exposure to significant geopolitical narratives, specifically the "Iran Deal Geopolitical Shift," "China US Export Controls," and "US Iran Peace Talks." Each of these sagas carries an intensity score of 0.4587, suggesting that while the company itself has not reported material internal changes, its operating environment is influenced by these high-level macroeconomic and political developments. Investors should monitor how these external factors may impact the company’s future performance, given the current lack of internal catalysts.
Signals & dispatch
Composite-score breakdown
Synthesis
Joint Corp (JYNT.O) is a healthcare company operating within the Healthcare Facilities & Services industry, with activities focused on biotechnology. The firm generates revenue through service-based models typical of the healthcare services sector. Specific details regarding its operating segments, headquarters location, and primary stock exchange listing are not available in the provided data.
Joint Corp maintains a strong liquidity position, with $17.46 million in cash and equivalents, representing 21.2% of total assets. The company's price-to-book ratio of 5.05 suggests a premium valuation relative to its book value, while the price-to-tangible-book ratio is identical, indicating no intangible asset discounting. The company's liquidity risk is assessed as low, with no immediate filing-based liquidity flags detected.
Profitability metrics show a challenging performance, with a negative return on equity of -15.51% and a return on assets of -4.36%, both significantly below industry norms. Operating income is negative at -$1.78 million, and net income is -$3.60 million, indicating operational inefficiencies or high costs relative to revenue.
Geographic and segment exposure is not explicitly detailed in the available data, but the company's revenue is concentrated in a single business line, as no segment breakdown is provided. This lack of diversification may increase exposure to sector-specific risks.
The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. Analysts have assigned a mean price target of $10.00, suggesting a potential upside from the current market price of $8.21. However, the absence of positive earnings and the negative operating cash flow of $1.84 million raise concerns about long-term growth sustainability.
Risk factors include the company's negative net income and operating income, which could impact its ability to service debt or fund operations without external financing. The dilution risk is assessed as low, with no immediate filing-based dilution flags detected. However, the company's free cash flow is negative at -$448,610, which may necessitate future capital raises.
Recent events include the publication of the latest financial data, which shows a revenue of $12.61 million and a gross profit of $9.80 million. No recent filings or transcripts have been disclosed that would indicate significant operational or strategic changes.
Joint Corp (JYNT.O) is currently undergoing its first formal analysis, meaning there is no prior historical basis for computing material changes or delta metrics. Consequently, the most significant immediate observation is the establishment of a baseline rather than a specific operational shift. The company’s profile is defined by a lean leadership structure with two officers and a modest analyst following of two, indicating limited institutional scrutiny at this stage. In terms of market visibility, Joint Corp is not currently a member of any major indices, which may limit its exposure to passive investment flows. However, the company maintains a shareholder base comprising 20 top holders, suggesting a degree of concentrated ownership despite the lack of broad index inclusion. This structure implies that price movements may be more sensitive to actions by these key stakeholders than to broader market trends. Recent monitoring data reveals a notable spike in activity on June 14, 2026, when one dispatch was recorded, breaking a streak of zero daily dispatches from May 25 through June 13. This isolated event marks the first instance of tracked communication or data release in the observed 30-day window, potentially signaling the beginning of increased transparency or a specific corporate announcement that warrants further investigation. The broader context for Joint Corp includes exposure to significant geopolitical narratives, specifically the "Iran Deal Geopolitical Shift," "China US Export Controls," and "US Iran Peace Talks." Each of these sagas carries an intensity score of 0.4587, suggesting that while the company itself has not reported material internal changes, its operating environment is influenced by these high-level macroeconomic and political developments. Investors should monitor how these external factors may impact the company’s future performance, given the current lack of internal catalysts.
- Joint Corp has a strong liquidity position with $17.46 million in cash and equivalents.
- The company's profitability is weak, with a negative return on equity and return on assets.
- Analysts have a cautiously optimistic outlook, with a mean price target of $10.00.
- The company's free cash flow is negative, indicating potential future capital needs.
- No immediate liquidity or dilution risks have been identified.
Bull / Bear case
Generated · model-assistedJoint Corp achieved a net income of $2.9 million in FY2026, marking a significant recovery from the previous year's loss.
The company eliminated all long-term debt by FY2025, resulting in a zero debt-to-equity ratio and reduced financial risk.
Analysts assign a mean price target of $10.00, suggesting approximately 8.9% upside from the current market price of $9.18.
Operating income improved by 51.6% year-over-year in FY2026, demonstrating progress in stabilizing core operational profitability.
The company faces high credit risk, signaling potential difficulties in meeting financial obligations or securing favorable financing terms.
Revenue has declined at a 9.0% compound annual growth rate over the last four years, reflecting a shrinking business scale.
In focus — financials by report
Revenue $14.8M, +13,3% YoY.
- ▍Revenue $14.8M, +13,3% YoY
Revenue $15.2M, +3,1% YoY; Operating income −8,3% YoY.
- ▍Revenue $15.2M, +3,1% YoY
- ▍Operating income −8,3% YoY
- ▍Net income +5 508,9% YoY
- ▍Free cash flow −12,7% YoY
- ▍Net margin 6.5%
Revenue $13.4M, +5,7% YoY; Operating income +132,7% YoY.
- ▍Revenue $13.4M, +5,7% YoY
- ▍Operating income +132,7% YoY
- ▍Net income +127,0% YoY
- ▍Free cash flow −25,0% YoY
- ▍Net margin 6.4%
Revenue $13.3M, +5,2% YoY; Operating income +36,0% YoY.
- ▍Revenue $13.3M, +5,2% YoY
- ▍Operating income +36,0% YoY
- ▍Net income +102,6% YoY
- ▍Free cash flow −139,7% YoY
- ▍Net margin 0.7%
Revenue $13.1M; Operating income -$678.5k.
- ▍Revenue $13.1M
- ▍Operating income -$678.5k
- ▍Net margin 6.1%
Revenue $14.7M; Operating income $809.7k.
- ▍Revenue $14.7M
- ▍Operating income $809.7k
- ▍Net margin 0.1%
Revenue $12.7M; Operating income -$492.8k.
- ▍Revenue $12.7M
- ▍Operating income -$492.8k
- ▍Net margin -25.0%
Revenue $12.6M; Operating income -$1.8M.
- ▍Revenue $12.6M
- ▍Operating income -$1.8M
- ▍Net margin -28.5%
Revenue $54.9M, +5,2% YoY; Operating income +51,6% YoY.
- ▍Revenue $54.9M, +5,2% YoY
- ▍Operating income +51,6% YoY
- ▍Net income +150,2% YoY
- ▍Free cash flow −103,0% YoY
- ▍Net margin 5.3%
Revenue $52.2M, +11,0% YoY; Operating income −693,5% YoY.
- ▍Revenue $52.2M, +11,0% YoY
- ▍Operating income −693,5% YoY
- ▍Net income +40,6% YoY
- ▍Free cash flow +113,3% YoY
- ▍Net margin -11.1%
Revenue $47.0M, −53,6% YoY; Operating income −61,6% YoY.
- ▍Revenue $47.0M, −53,6% YoY
- ▍Operating income −61,6% YoY
- ▍Net income −1 656,1% YoY
- ▍Free cash flow −1 154,4% YoY
- ▍Net margin -20.8%
Revenue $101.3M, +26,6% YoY; Operating income −86,5% YoY.
- ▍Revenue $101.3M, +26,6% YoY
- ▍Operating income −86,5% YoY
- ▍Net income −91,7% YoY
- ▍Free cash flow −69,4% YoY
- ▍Net margin 0.6%
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,25 |
| Revenue | —no estimate | —no estimate | 60,4M USD |
| Operating income | —no estimate | —no estimate | 5,3M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Joint Corp Market data — financials · 2026-05-28
- Joint Corp Market data — analyst estimates · 2026-05-28
- Joint Corp Market data — ESG · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2024-06-300,00 %$11M
- Investment Managers · as of 2024-12-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2025-12-310,00 %$9M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Peter D. HoltPresident, Chief Executive Officer, Director
- Sanjiv Kumar RazdanPresident, Chief Executive Officer, Director
Insider activity
- Chief Financial Officer · Common StockOther 1 392 @ $8,43$12K · 2026-06-10
- Director · Common StockOther 5 714 · 2026-05-20
- Director · Common StockOther 5 714 · 2026-05-20
- Director · Common StockOther 5 714 · 2026-05-20
- Director · Common StockOther 5 714 · 2026-05-20
- Director · Common StockOther 5 714 · 2026-05-20
- 10% owner · CommonBought 20 375 @ $8,57$175K · 2026-05-13
- 10% owner · CommonBought 127 676 @ $8,57$1,1M · 2026-05-12
- 10% owner · CommonBought 509 @ $8,58$4K · 2026-04-21
- Chief Financial Officer · Common StockOther 28 301 · 2026-03-09
- Director, See Remarks · Common StockOther 73 484 · 2026-03-09
- 10% owner · CommonBought 15 397 @ $8,50$131K · 2026-02-12
- 10% owner · CommonBought 448 @ $8,70$4K · 2026-02-11
- 10% owner · CommonBought 725 @ $10,00$7K · 2026-01-26
- 10% owner · CommonBought 16 753 @ $10,00$168K · 2026-01-23
- 10% owner · CommonBought 5 240 @ $8,89$47K · 2026-01-06
- 10% owner · CommonBought 1 393 @ $8,70$12K · 2026-01-02
- 10% owner · CommonBought 11 @ $8,70$96 · 2025-12-31
- 10% owner · CommonBought 10 000 @ $8,41$84K · 2025-12-05
- 10% owner · Common StockBought 13 000 @ $8,41$109K · 2025-12-01
- 10% owner · Common StockBought 2 081 @ $8,43$18K · 2025-11-25
- 10% owner · Common StockBought 4 680 @ $8,36$39K · 2025-11-24
- 10% owner · Common StockBought 10 000 @ $8,50$85K · 2025-11-21
- Director · Common StockBought 10 000 @ $10,41$104K · 2025-08-20
- Director · Common StockBought 10 000 @ $10,70$107K · 2025-08-18
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -5.8%Derived (calculated)
- Return on equity (FY 2025-12-31): 19.3%Derived (calculated)
- Return on assets (FY 2025-12-31): 4.8%Derived (calculated)
- Current ratio (FY 2025-12-31): 1.59xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 3.05xDerived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 26.8%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -2.5%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 148.7%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 150.0%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 150.2%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -80.5%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 51.6%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -27.1%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -26.7%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -26.6%Derived (calculated)
- Current assets (annual): USD 52.09MSEC XBRL filing
- Total assets (annual): USD 60.97MSEC XBRL filing
- Cost of revenue (annual): USD 11.23MSEC XBRL filing
- Net income (annual): USD 2.91MSEC XBRL filing
- Operating cash flow (annual): USD 1.84MSEC XBRL filing
- Current liabilities (annual): USD 32.82MSEC XBRL filing
- Capex (annual): USD 1.5MSEC XBRL filing
- Total liabilities (annual): USD 45.89MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES 0SEC XBRL filing